# Dexcom Ventures

Dexcom Ventures is a Venture Capital based in San Diego, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, United States
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** dexcomventures.com
- **LinkedIn:** https://www.linkedin.com/company/dexcom

## Regulatory record

- **Reports private funds:** No

## About

Dexcom develops glucose biosensing technology for the healthcare sector, primarily for diabetes management. Its products include continuous glucose monitoring systems that provide glucose readings without fingersticks. Founded in 1999, Dexcom is based in San Diego, California.

## Sectors

- Digital Health
- Medical Devices
- Cybersecurity
- AI/ML

## People

- Jason Halac — Managing Director, Dexcom Ventures
- Adam Seivert — Analyst, Dexcom Ventures

## Questions

### Who runs investment decisions at Dexcom Ventures?

Jason Halac, co-founder and Managing Director, leads technology scouting and strategic pipeline development for Dexcom Ventures. He is supported by Analyst Adam Seivert, who handles co-investor networking, sourcing, due diligence, and portfolio management. The small team structure means Halac is directly involved in investment decisions, reflecting the unit's tight alignment with Dexcom's corporate strategy.

### Does Dexcom Ventures participate in fund commitments or only direct deals?

Based on its disclosed portfolio of direct investments into companies such as Epitel, Beta Bionics, and Nutromics, Dexcom Ventures focuses on direct equity stakes in startups. There is no public evidence that it makes commitments as a limited partner into external venture funds. Its model is to take direct positions where it can add strategic value alongside its capital.

### What investment stages does Dexcom Ventures typically target?

Dexcom Ventures seeks out promising transformational technology platforms, often describing its bets as contrarian or symmetrical. The specific stage preference is not publicly disclosed, but its portfolio includes companies ranging from early commercial-stage ventures like Epitel and Nutromics to more developed platforms approaching or having achieved regulatory milestones, such as Beta Bionics.

### Which sectors does Dexcom Ventures focus on?

The unit concentrates on biosensing technology, data-driven healthcare, and adjacent medical device fields. Its portfolio features continuous molecular monitoring (Nutromics), remote patient monitoring (BiointelliSense), AI-powered weight management combining CGM data (Signos), medical device cybersecurity (Medcrypt), and automated insulin delivery (Beta Bionics). The common thread is sensor-driven, personalized health data.

## Related profiles

- [Dexa International](https://altss.com/profile/dexa-international)
- [Dexia](https://altss.com/profile/dexia)

---

Last updated: 2026-07-06T00:32:51.621Z

Canonical page: https://altss.com/profile/dexcom-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology